China Resources Pharmaceutical Group Ltd Registered Shs Unitary 144A/Reg S
03320: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$6.10 | Xqjgtxk | Rrdcfxp |
CR Pharma's Full-Year Results Show Signs of Recovery, Profit Margins Improve
Narrow-moat CR Pharma reported earnings that were slightly better than our expectation. Although revenue growth was weak, this was more than made up for by lower selling, general, and administrative, or SG&A, expenses. Additionally, the company’s working capital metrics such as accounts receivable days and inventory days have completely normalized, indicating a recovery from the COVID-19-stricken first half.